
## Andrew V Gomez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5462926/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inhibition of IKKÉ› and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. Cell Metabolism, 2017, 26, 157-170.e7.	16.2	127
2	Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKK <i>ε</i> and Reveal Mechanisms for Selective Inhibition. Molecular Pharmacology, 2018, 94, 1210-1219.	2.3	36
3	ERRÎ <sup>3</sup> Preserves Brown Fat Innate Thermogenic Activity. Cell Reports, 2018, 22, 2849-2859.	6.4	30
4	Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases TBK1 and IKKIµ for the treatment of obesity. Bioorganic and Medicinal Chemistry, 2018, 26, 5443-5461.	3.0	29
5	Catecholamines suppress fatty acid re-esterification and increase oxidation in white adipocytes via STAT3. Nature Metabolism, 2020, 2, 620-634.	11.9	25
6	FGF21 is required for the metabolic benefits of ΙΚΚĴμ/ΤΒΚ1 inhibition. Journal of Clinical Investigation, 2021, 131, .	8.2	7